TET2 and acute myeloid leukemia: Regarding cytogenetic risk, we found that mutant TET2 had an inferior impact on RFS in IR‐AML (2‐year RFS: 0% vs 75.2%, P = .004) as well as in CN‐AML (2‐year RFS: 0% vs 83.9%, P < .001) (Figure S4A‐B).